US President Donald Trump defended his claims about prescription drug price reductions during a White House event announcing a deal with pharmaceutical company Regeneron. The event focused on lowering medication costs, but Trump’s remarks drew attention after he reiterated figures suggesting price cuts exceeding 100 per cent, which economists say is mathematically incorrect.

During the event, Trump said he had previously described drug price reductions as “500 per cent, 600 per cent,” while also suggesting alternative calculations that could show reductions of 50 to 90 per cent. He stated that “there are two ways of calculating” such figures and argued that either interpretation reflected meaningful savings for consumers.

However, experts note that percentage reductions above 100 per cent are not mathematically possible in standard pricing terms, as a full 100 per cent reduction would bring a price to zero. Any further reduction would imply negative pricing, where consumers would be paid to take a product, which does not occur in real-world pharmaceutical markets.

Also Read: Vice-President Stresses Last-Mile Delivery And Integrity On Civil Services Day Event

Health and Human Services Secretary Robert F. Kennedy Jr., speaking at the same event, defended the administration’s framing by arguing that some drug prices had previously increased by more than 100 per cent before being significantly reduced. He suggested that Trump’s figures reflected the scale of those earlier price hikes, though he acknowledged the unusual way the calculations were being presented.

The discussion over pricing mathematics came shortly after Trump also referenced other disputed claims, including the duration of the Iran conflict and historical crowd sizes at his 2017 inauguration. The president maintained that his earlier statements were consistent with his interpretation of events, despite established records and widely cited data differing from his accounts.

The remarks added to ongoing debate over the administration’s messaging on economic and policy achievements, particularly in relation to healthcare pricing. While the White House event was intended to highlight efforts to reduce prescription drug costs, attention instead shifted to the accuracy of the figures used to describe those reductions.

Also Read: MEA Responds To Trump Truth Social Post Calling India And China “Hellholes”